Gunze's Latest ActivitiesPosted on February 24, 2022 Gunze Launches TENALEAF™ Absorbable Adhesion Barrier in Japantailored to medical professionals to improve patient clinical outcomePosted on September 16, 2021 Announcing the use of Gunze’s meniscal repair biodegradable scaffolds for a clinical trial to improve the outcome of medial meniscal injury patients at Osaka Medical and Pharmaceutical UniversityPosted on September 16, 2021 Launch of Gunze’s U.S. Medical Division WebsitePosted on September 24, 2020 Gunze provides biodegradable scaffolds for TEVG clinical trial to be conducted at the Abigail Wexner Research Institute at Nationwide Children’s Hospital to improve pediatric patient clinical outcomePosted on September 24, 2020 Gunze Enters into Exclusive Supply and Distribution Agreement with Misonix for TheraGenesis® Bilayer Wound Matrix in U.S. MarketPosted on April 29, 2020 PELNAC® Bilayer Wound Matrix Receives U.S. Food and Drug Administration (FDA) Clearance
Posted on February 24, 2022 Gunze Launches TENALEAF™ Absorbable Adhesion Barrier in Japantailored to medical professionals to improve patient clinical outcome
Posted on September 16, 2021 Announcing the use of Gunze’s meniscal repair biodegradable scaffolds for a clinical trial to improve the outcome of medial meniscal injury patients at Osaka Medical and Pharmaceutical University
Posted on September 24, 2020 Gunze provides biodegradable scaffolds for TEVG clinical trial to be conducted at the Abigail Wexner Research Institute at Nationwide Children’s Hospital to improve pediatric patient clinical outcome
Posted on September 24, 2020 Gunze Enters into Exclusive Supply and Distribution Agreement with Misonix for TheraGenesis® Bilayer Wound Matrix in U.S. Market
Posted on April 29, 2020 PELNAC® Bilayer Wound Matrix Receives U.S. Food and Drug Administration (FDA) Clearance
